Open AccessIs cabozantinib the common answer to all radioiodine-refractory differentiated thyroid cancers?
Author(s) -
Akhil Kapoor,
VijayM Patil,
Kumar Prabhash
Publication year - 2022
Publication title -
cancer research, statistics, and treatment/cancer research, statistics and treatment
Language(s) - English
Resource type - Journals
eISSN - 2590-3233
pISSN - 2590-3225
DOI - 10.4103/crst.crst_15_22
Subject(s) - cabozantinib , refractory (planetary science) , medicine , thyroid cancer , oncology , thyroid , cancer research , cancer , biology , astrobiology